Drug genetic associations with COVID-19 manifestations: a data mining and network biology approach.
Pharmacogenomics J
; 22(5-6): 294-302, 2022 12.
Article
in En
| MEDLINE
| ID: mdl-36171417
ABSTRACT
Available drugs have been used as an urgent attempt through clinical trials to minimize severe cases of hospitalizations with Coronavirus disease (COVID-19), however, there are limited data on common pharmacogenomics affecting concomitant medications response in patients with comorbidities. To identify the genomic determinants that influence COVID-19 susceptibility, we use a computational, statistical, and network biology approach to analyze relationships of ineffective concomitant medication with an adverse effect on patients. We statistically construct a pharmacogenetic/biomarker network with significant drug-gene interactions originating from gene-disease associations. Investigation of the predicted pharmacogenes encompassing the gene-disease-gene pharmacogenomics (PGx) network suggests that these genes could play a significant role in COVID-19 clinical manifestation due to their association with autoimmune, metabolic, neurological, cardiovascular, and degenerative disorders, some of which have been reported to be crucial comorbidities in a COVID-19 patient.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
COVID-19 Drug Treatment
Type of study:
Risk_factors_studies
Limits:
Humans
Language:
En
Journal:
Pharmacogenomics J
Journal subject:
BIOLOGIA MOLECULAR
/
FARMACOLOGIA
Year:
2022
Document type:
Article
Affiliation country:
Greece